ArticleJournal of clinical apheresis2026
Using Preoperative Therapeutic Plasma Exchange in Lupus Anticoagulant Hypoprothrombinemia Syndrome to Achieve Hemostatic Factor II Activity: A Case Report.
Article in Journal of clinical apheresis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lupus anticoagulant hypoprothrombinemia syndrome (LA-HPS) is a rare cause of acquired factor II deficiency associated with lupus anticoagulant due to antiprothrombin antibody, which predisposes to bleeding rather than thrombosis. We report a case of a 48-year-old female with LA-HPS resulting in a bleeding diathesis due to acquired prothrombin or factor II (FII) deficiency in the context of very high titers of anti-phosphatidylserine/prothrombin antibodies (anti-PS/PT). In preparation for elective mitral valve replacement surgery due to infective endocarditis, she received four sessions of therapeutic plasma exchange (TPE) preoperatively, followed by IVIG (2 g/kg total in divided doses). Her FII activity improved from 7% to 53% on the morning of her surgery, and her IgM anti-PS/PT decreased from greater than 150 units to a nadir of 26.4 units. She completed the surgery without bleeding complications. She has since been maintained on immunosuppression with mycophenolate and without bleeding. We illustrate one of the few reported successful uses of TPE to effectively remove the anti-PS/PT antibodies and optimizing hemostasis by increasing FII activity before a surgical procedure to mitigate the high bleeding risk. We also add to the limited existing evidence that immunosuppression is a reasonable long-term treatment in patients with anti-prothrombin antibodies causing severe hypoprothrombinemia with bleeding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.